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Abstract: Ovarian cancer is both difficult to detect and difficult to treat, therefore the 
discovery of new therapies is important. Retinoids (retinoic acid derivatives) are known 
to induce cellular apoptosis in various cancers, especially in ovarian cancer. Retinoids are 
also highly cytotoxic to healthy cells, however. SHetA2 leads a class of retinoids known 
as Flexible Heteroarotinoids (Flex-Hets) that have low toxicity to healthy cells while 
retaining anti-cancer activity. Rigorous studies of the structure-activity relationship of 
retinoids and heteroarotinoids have determined that 5-membered heterocyclic Ring A 
systems in SHetA2 analogs might exhibit anti-cancer activity as well as improved water 
solubility. The synthetic challenge in preparing these molecules led to the investigation of 
a new synthetic route for preparing SHetA2 analogs. This new route involves cyclizing 
tethered alkenes via a reductive Heck reaction using the Jeffery conditions. This reaction 
is known to prepare heterocycles that contain structural characteristics essential to 
SHetA2 analog anti-cancer activity. This study synthesized a new class of 
heteroarotinoids using this method, then explored other ways in which the method could 
be applied to the greater project. The method was also employed to synthesize a 
previously known heterarotinoid, OHet72, as well as a new analog of that compound. In 
addition, the synthesis of bacterioferritin-inhibiting antibiotics was explored, including 
the preparation of a specific substrate designed to provide insight into a problem 
observed in the synthesis of previous analogs. This substrate required a new synthetic 
approach, and was designed to eliminate the possibility of various side reactions 
occurring. This study explored the preparation of 4-((5-chloro-2-
hydroxybenzyl)amino)isoindolin-1-one and whether similar side reactions were observed. 
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SYNTHESIS OF HETEROAROTINOIDS FOR ANTI-CANCER ACTIVITY 
1.1 Introduction 
 Ovarian cancer has been dubbed a “silent killer” because 80% of patients fail to exhibit 
symptoms before the disease has reached advanced stages.1 In fact, ovarian cancer poses the 
highest mortality rate among gynecological cancers, with around 13,940 deaths and 21,750 
diagnoses annually in the United States.2 Effective treatment and drug options for this disease 
remain elusive.  
 Retinoids, including retinoic acid (1) (Figure 1.1), and their synthetic analogs are known 
to induce cellular differentiation and apoptosis.3 Consequently, medicinal chemists regard these 
compounds as potential anti-cancer agents; however, the toxicity of retinoids towards healthy 
cells remains a problem.4 One class of synthetic retinoid analogs, Flexible Heteroarotinoids (Flex-
Hets), has been shown to retain anti-cancer activity without toxicity to healthy cells.5 The parent 
compound in this series is SHetA2 (3) (Figure 1.1), which displays activity towards various 
cancers, including ovarian cancer.6 
Heteroarotinoids have been known for more than three decades.7 Several reviews have 
addressed this type of class of heterocycles, many of which have anti-cancer properties.6, 8-9 
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The initial theory was that a heteroarotinoid system might exhibit reduced toxicity compared10 to 
retinoic acid (1), which was the primary model.7 However, it has been documented that retinoids 
are quite toxic,11 and thus, have limited utility at this time. One of the original heteroarotinoids was 
27 which contained a highly conjugated system as in 1. Many modifications of the basic structure 
have appeared in the literature,9 and have led to the compound 3, which is awaiting clinical trial for 
the prevention of ovarian cancer.  
 
Figure 1.1: Structure of Retinoic Acid 1, and its evolution into heteroarotinoids. 
A toxicity assessment of 3 in rats and dogs revealed no observed adverse effect level 
(NOAEL) at 500 mg/kg/day and 1500 mg/kg/day, respectively.12 A recent study of the 
pharmacokinetics and interspecies scaling of oral-bioavailability resulted in an estimate that a 
capsule containing 170 mg of SHetA2 for a person (based on 2 mg/kg for an 85 kg individual) was 
conceivable.13  Additional research is required to substantiate this dosage for humans.  
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The major metabolites for SHetA2 have been identified.14  Two such metabolites, 6 and 7, 
are illustrated below. It was reasoned that such systems might be responsible, or partially 
responsible, for the biological activity derived from SHetA2. Speculation was that related 
compounds, such as 4 and 5, might hold promise for useful activity. 
Figure 1.2: Metabolites of SHetA2. 
The preparations of 4 and 5 have been consummated, and the work has been accepted for 
publication.15 Although not an exact match for compound 7, compounds 4 and 5 have the added 
capability to be solubilized by acid addition to the nitrogen atom, which should increase aqueous 
solubility. Moreover, several early examples in the heteroarotinoid family had enhanced activity 
with a urea linker over that with a thiourea linker, the former being included in 4 and 5.15 Thus, 
members of 4 had improved activity over SHetA2 in both IC50 and efficacy values (2.58 ± 0.1 and 
90.1 ± 1.4 for the system with CF3 and 2.4 ± 0.2 and 91.3 ± 1.3 for the system with OCF3, 
respectively). These data compared well with that for SHetA2 (3.17 ± 0.05 and 84.3 ± 0.7, 
respectively). Unexpectedly, members of 5 had reduced activity compared to SHetA2.   
It is known that SHetA2 interacts with the heat shock protein mortalin.16 Obviously, the 
binding site in mortalin has considerable restrictions, based on data from the above experiments.  
Hydrophobic interaction of the top geminal dimethyl group appears to be important for binding to 
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mortalin. Because of the nearness in structure of 8 to the metabolite 7, the synthesis of 8 was 
accomplished.17  However, it did not possess activity better than SHetA2.18 
An investigation was initiated by altering the alkyl groups at the 2-position and the 4-
position, changing the heteroatom in the fused ring, and changing the linker to a urea.19  Replacing 
the methyl groups on the fused ring with ethyl groups resulted in a marked improvement in the IC50 
(50% inhibitory concentration) values as well as the efficacy values for all members of 9-11.  The 
IC50 values and efficacy values were as follows: for 9 (R = NO2, 2.17 and 93.2%, R = CF3, 2.45 
and 92.4%), for 10 (R = NO2, 2.05 and 93.7%, R = CF3, 2.43 and 93.3%), and for 11 (R = NO2, 
2.09 and 91.4% and for R = CF3, 2.0 and 91.4%). By comparison, the data for SHetA2 were 3.17 
and 93.9, respectively, for IC50 and efficacy values. Clearly the presence of oxygen in the fused 
ring, a urea linker, and the ethyl groups at both C-2 and C-4 are significant constructs for enhanced 
biological activity.   
 
Figure 1.3: Compounds that identified important structural characteristics. 
 It occurred to us that a different fused ring size might well influence activity.  Systems 12 
and 13 are known,20-21 and members of 12 actually induce differentiation of human promyelocytic 




Figure 1.4: Retinoids featuring a 5-membered fused ring. 
However, a possibility existed that systems 14 might exhibit useful anti-cancer activity and they 
were targeted for synthesis as shown in the next chapter of this dissertation. 
 
Figure 1.5: Structure of target derivatives and a noteworthy compound. 
 It is noteworthy that a recent observation of a novel fused ring unit bonded to a chiral 
center, which, in turn, was bonded to a thiourea linker attached to a phenyl ring showed strong 
activity against several breast cell lines.22 Compound 15 displayed activity during a cell cycle 
analysis involving human breast cancer cell lines MCF-7, T47D, and MDA-MB-453 when treated 
with 5.0 µM of the (S)-isomer. The publication summarizes considerable biology/chemistry of 
heteroarotinoids. Thus, the field remains viable for further development. 
In order to further develop SHetA2 analogs as anti-cancer therapeutics, derivatives similar 
to 14 need to be synthesized. These analogs must further explore diversification of the functionality 




Figure 1.6: The composition of SHetA2 and its analogs. 
Ideal analogs would retain or improve upon the potency and efficacy of SHetA2, while displaying 
improved solubility (especially in water) and reduced potential for mutagenic metabolites forming 
by way of the -NO2 group.  
 This study will address the synthesis of fused, five-membered rings in the Ring A system. 
The rings are also functionalized with both urea and thiourea linker units, and with various electron 
withdrawing groups (EWG) bound to the Ring B system. Specifically, the study involves the 
development of efficient synthetic approaches to indoline and dihydrofuran-containing SHetA2 
analogs (Figure 1.7). 
 
Figure 1.7: Target heteroarotinoids in this study. 
 Additionally, this study will discuss a new synthesis of OHet72 (16), a previously prepared 
heteroarotinoid (Figure 1.8). OHet72 is classified as a receptor-specific heteroarotinoid, and is 





Figure 1.8: OHet72, a heteroarotinoid of renewed interest. 
 Finally, this study will show the synthesis of a dihydrofuran analog 17 of OHet72 (16) 
(Figure 1.9). The purpose of synthesizing this analog was to demonstrate that the method used to 
synthesize OHet72 (16) and several prior analogs was sufficiently versatile to access many 
candidates for this project. 
 
Figure 1.9: A dihydrofuran analog of OHet72. 
 This study aims to introduce and demonstrate a facile, effective synthetic route to 
synthesize modified Ring A systems (Figure 1.6) that are of importance to anti-cancer activity. The 
reaction of interest is an intramolecular cyclization via a ligand-free, palladium catalyzed reductive 
Heck using the Jeffery conditions. From the time it was originally reported in the early 1970’s, the 
Mizoroki-Heck reaction has been a powerful tool in organic synthesis due to its ability to generate 
aryl-alkyl C-C bonds (Figure 1.10).24-25 Due to the numerous and diverse applications of the 
Mizoroki-Heck reaction, many studies have been performed aimed at expanding the reaction’s 
scope. Catellani catalytically obtained H-transfer from various hydride sources to form reduced 
products of the Mizoroki-Heck reaction.26 Jeffery reported adding tetraalkylammonium salts to the 
Mizoroki-Heck reaction resulting in significant lowering of the reaction temperature.27 Larock 
synthesized nitrogen heterocycles by performing the Mizoroki-Heck reaction on alkenes tethered 
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to o-haloanilines.28 By employing the Jeffery conditions, and, when applicable, hydride sources, 
Larock prepared various nitrogen heterocycles at relatively mild temperatures (80 – 90 °C) and in 
good to excellent yields.28 Liu and coworkers report this method as pathway to synthesize a wide 
array of heterocycles.29  
 
Figure 1.10: The catalytic cycle of a classic Heck reaction. 
 The classic Mizoroki-Heck reaction is characterized by the retention of the alkene in the 
cross-coupled product. The regeneration of the alkene occurs due to a β-hydride elimination (Figure 
1.10), which is considered the thermodynamically favored process.30 In order to obtain the reduced 
product, several adjustments must be made to the reaction, specifically the processes reported by 
Catellani and Jeffery.26-27 Addition of a hydride source and use of tetraalkylammonium salts to 
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lower the heat input to the reaction introduces a competing mechanism.31 With these conditions, β-
hydride elimination is in competition with a ligand exchange of a hydride for a halogen, followed 
by subsequent C-H bond formation upon reductive elimination of the catalyst.32 Lastly, the 
reductive product can be further favored by the use of an alkene void of a β-hydrogen (Figure 
1.11).33  
 
Figure 1.11: A possible catalytic cycle for an intramolecular reductive Heck cyclization. 
One advantage of this method is the tolerance, and even requirement of, the presence of 
water, thus avoiding rigorously anhydrous reagents and reaction conditions.29 A second advantage 
is the ability of the reaction to tolerate various functional groups.29 This makes the method versatile, 
and therefore potentially very useful in the synthesis of SHetA2 analogs. The Jeffery conditions 
are essential to the success of this reaction. The tetraalkylammonium salt used in the Jeffery 
procedure functions both as a phase-transfer catalyst27 and as a palladium nano-particle stabilizing 
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agent.34 By using and studying this method, heterocycles can be synthesized that includes the top 
germinal dimethyl groups that are essential to anti-cancer activity in heteroarotinoids. 
1.2 Synthesis of Indoline SHetA2 Analogs 
 Interest in fused indoline-containing SHetA2 analogs developed due to the potential of this 
functional group to increase the solubility of SHetA2, and thus its potency, similar to 4 and 5. The 
potential usefulness of 4, 5, and 12 also increased interest. Making this adjustment to the Ring A 
system would also reveal the importance of the structure of Ring A in anti-cancer activity.  
 With these goals established, we designed and synthesized sixteen SHetA2 analogs 
characterized by a fused, N-methylindoline Ring A system, urea and thiourea linker units, and 4-
NO2, CN, CF3, and OCF3 functionalized Ring B systems. We now report the synthesis and 
biological activity of these Flex-Hets against the ovarian cancer cell line A2780. These new 
heteroarotinoids were appraised relative to SHetA2. 
1.2.1 Results and Discussion 
Synthesis of fused, N-methylindoline SHetA2 analogs required 7 steps. First, 2-bromo-4-
nitroaniline (18) was treated with acetic anhydride in glacial acetic acid at room temperature to 
afford the acetamide product 19 in 84% yield. Subsequent alkylation of 19 with 3-iodo-2-
methylprop-1-ene at 60 °C led to the formation of the tertiary amide 20 in quantitative yield. 
Cyclization of 20 via a reductive Heck reaction using Jeffery conditions at 85 °C afforded the cyclic 
amide 21 in 85% yield.35 Amide 21 was hydrolyzed with refluxing 20% HCl to afford indoline 22 
in 94% yield. Indoline 22 was methylated but treatment with NaH followed by dropwise addition 
of methyl iodide to generate N-methylindoline 23 in quantitative yields. Treating 23 with iron and 
ammonium chloride in a refluxing ethanol-water mixture (4:1) afforded aniline derivative 24 in 
80% yield. Finally, aniline derivative 24 was treated by dropwise addition of isocyanates and 
isothiocyanates 25a-h to afford the SHetA2 analogs 26-33 in 21-75% yields (Scheme 1.1). Reaction 
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yields in the final step were dependent upon the purity of the commercial isocyanates and 
isothiocyanates. 
 
Scheme 1.1: The synthesis of Indoline SHetA2 Analogs. 
All products 26-33 were purified on a 10 inch silica gel column, eluting with 10% ether in hexanes, 
increasing the polarity on a gradient to 50% ether in hexanes. All products were subsequently dried 
under vacuum at 60 °C for 24 hours. 
The biological effects of the compounds were determined by cytotoxicity assay of the 
human A2780 ovarian cancer cell line (Table 1.1). All compounds showed decreased potency and 
significantly decreased efficacy compared to SHetA2. Compound 26 showed the highest efficacy 
of the candidates, with 44.87% efficacy of SHetA2. Compound 26 is functionalized with a urea 
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linker unit and a -NO2 group on Ring B, indicating that one or both of those functionalities lead to 
improved efficacy. With no otherwise observable trend in the differences in potency and efficacy 
when varying the linker unit and the Ring B functionality, this study demonstrated the importance 
of the Ring A structure in the biological activity of SHetA2 analogs. Unfortunately, the synthesized 
fused N-methylindoline derivatives were marginal in anti-cancer activity. 
 
Table 1.1: The biological activity of indoline SHetA2 analogs relative to SHetA2. 
1.3 Synthesis of Dihydrofuran SHetA2 Analogs 
 Interest in fused dihydrofuran-containing SHetA2 analogs were developed with the desire 
to increase the solubility of SHetA2, and thus its potency. The usefulness of 9-11 also increased 
interest. Making this adjustment to the Ring A system could also reveal the importance of the 
structure of Ring A in anti-cancer activity.  
 With these goals in mind, we designed and synthesized sixteen SHetA2 analogs 
characterized by a fused, dihydrofuran Ring A system, urea and thiourea linker units, and 4-NO2, 
CN, CF3, and OCF3 functionalized Ring B systems. We now report the synthesis and biological 
activity of these Flex-Hets against the ovarian cancer cell line A2780. These new heteroarotinoids 
were evaluated relative to SHetA2. 
1.3.1 Results and Discussion 
Compound X = R = Potency IC50 (µM) Maximal Activity (% growth inhibition) Efficacy (%SHetA2)
SHetA2 S NO2 3.45±0.10 80.76±2.41 100%
26 O NO2 6.14±0.20 36.24±3.13 44.87%
27 S NO2 5.91±0.26 21.58±2.66 26.72%
28 S CF3 6.15±0.26 18.43±2.25 22.82%
29 O CF3 6.34±0.26 28.21±2.99 34.93%
30 S CN 3.51±0.26 20.59±1.85 25.50%
31 O CN 3.89±0.23 19.19±2.10 23.76%
32 S OCF3 3.74±0.27 18.34±2.14 22.71%
33 O OCF3 5.95±0.30 22.79±3.18 28.22%
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 Synthesis of fused dihydrofuran analogs required 6 steps. First, 2-bromo-4-nitrophenol 
(34) was alkylated with 3-iodo-2-methylprop-1-ene to produce 35 in 72% yield. 
Scheme 1.2: The synthesis of dihydrofuran SHetA2 analogs. 
Nitrated ether 35 was treated with iron and ammonium chloride in a refluxing ethanol-water 
mixture (4:1) to afford 36 in 92% yield. Amide 37 was realized by treatment of the aniline analog 
36 with acetic anhydride in glacial acetic acid at room temperature and was isolated in 89% yield. 
Cyclization of 37 via a reductive Heck reaction using Jeffery conditions afforded cyclic ether 38 
in 95% yield. The aniline 39 was obtained in 82% yield by treatment of 38 with refluxing 20% 
HCl. Finally, 39 was treated with dropwise addition of isocyanates and isothiocyanates 25a-h to 
afford the SHetA2 analogs 40-47 in 24-95% yields (Scheme 1.2). Reaction yields in the final step 
were dependent upon the purity of the commercial isocyanates and isothiocyanates. All products 
40-47 were purified on a 10 inch silica gel column, eluting with 10% ether in hexanes, and 
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increasing the polarity on a gradient to 50% ether in hexanes. All products were subsequently 
dried under vacuum at 60 °C for 24 hours. 
Table 1.2: The biological activity data of dihydrofuran SHetA2 analogs relative to SHetA2. 
The biological effects of the compounds were determined by cytotoxicity assay against the 
human A2780 ovarian cancer cell line (Table 1.2). Compound 41 showed decreased potency and 
viable efficacy, compared to SHetA2. Compound 41 contains a urea linker unit and a 4-NO2 
group on Ring B, similar to indoline analog 26, but with improved efficacy compared to SHetA2. 
This is an indication that the dihydrofuran-containing Ring A system provides better activity than 
the indoline-containing Ring A system when combined with active linker and Ring B units. 
Compound 46 showed marked potency compared to SHetA2, and provided sufficient efficacy to 
be noteworthy. The influence in Ring B functionality by -OCF3 was noted, along with the urea 
linker unit. Compounds 42 and 43 showed improved potency relative to SHetA2, but much lower 
efficacy. This class of SHetA2 analogs revealed that this functionality of the Ring A system can 
provide compounds with improved potency and acceptable efficacy to SHetA2.   
1.4 Synthesis of OHet72 via a Reductive Heck Cyclization 
Interest in OHet72 (16) as an anti-cancer agent remains high. Herein, we report a facile synthesis 
of OHet72 using an intramolecular reductive Heck reaction using Jeffery conditions to cyclize the 
chroman ring.  
Compound X = R = Potency IC50 (µM) Maximal Activity (% growth inhibition) Efficacy (%SHetA2)
SHetA2 S NO2 3.45±0.10 80.76±2.41 100%
40 S NO2 4.14±0.40 21.36±3.51 26.45%
41 O NO2 6.09±0.12 62.98±3.72 77.98%
42 S CN 1.63±0.30 15.01±2.23 18.59%
43 O CN 1.31±0.40 19.54±2.65 24.20%
44 O CF3 3.60±0.17 35.48±2.51 43.93%
45 S CF3 6.15±0.21 25.31±2.54 32.34%
46 O OCF3 1.38±0.06 44.69±1.01 55.34%
47 S OCF3 7.95±0.32 17.65±3.39 21.85%
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1.4.1 Results and Discussion 
 
Scheme 1.3: The synthetic route to OHet72 via a reductive Heck cyclization. 
Synthesis of OHet72 (16) required 6 steps. First, 3-bromo-4-hydroxybenzoic acid (48) was 
converted to ester 49 by refluxing in ethanol with a catalytic amount of H2SO4, and ester 49 was 
recovered in 86% yield. Phenol 49 was then alkylated with 3-methylbut-3-en-1-yl 4-
methylbenzenesulfonate, and ether 50 was produced in 81% yield. Cyclization of 50 via a 
reductive Heck using Jeffery conditions afforded chroman derivative 51 in 94% yield. Ester 51 
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was next hydrolyzed to carboxylic acid 52 with KOH in ethanol at 89% yield. Ester-aldehyde 54 
was obtained by treating carboxylic acid 52 and 4-hydroxybenzaldehyde (53) in the presence of 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 4-dimethylaminopyridine (DMAP). 
A yield of 64% was obtained for 54. Finally, OHet72 (16) was realized by adding aqueous 
thiosemicarbazide to ester-aldehyde 54 in refluxing ethanol. 
1.5 Synthesis of Furan OHet72 Derivative via a Reductive Heck Cyclization 
 Renewed interest in OHet72 (16) presented the opportunity to synthesize new analogs of 
the compound. Herein we report a synthesis for a dihydrofuran-containing analog of OHet72 
(17), employing the Jeffery variant of the reductive Heck to cyclize the furan ring. 
1.5.1 Results and Discussion 
Synthesis of the dihydrofuran-containing analog 17 required 5 steps from a known precursor. 
First, ethyl 3-bromo-4-hydroxybenzoate (49) was alkylated with 3-iodo-2-methylprop-1-ene in 
98% yield. The ether product 55 was cyclized by employing an intramolecular reductive Heck 
under the Jeffery conditions to afford the benzofuran derivative 56 in 50% yield. In the 
cyclization step, a significant amount of rearranged enol ether byproduct was observed. The yield 
of the cyclized product was maximized when the palladium catalyst was added before heating, 
and then heating at 95 °C. The cyclized ester 56 was treated with KOH in ethanol to obtain 
carboxylic acid 57 in 96% yield after neutralization. Ester-aldehyde 58 was next obtained by 
esterification of carboxylic acid 57 and 4-hydroxybenzaldehyde (53) with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and 4-dimethylaminopyridine (DMAP). A yield of 
94% was realized for 58. Finally, OHet72 analog 17 was acquired by addition of aqueous 









 In summary, we have synthesized 18 heteroarotinoids by employing a powerful 
cyclization method. Additionally, in an attempt to improve the anti-cancer activity of SHetA2 (3), 
16 heteroarotinoids were assessed in a cytotoxicity assay of the human A2780 ovarian cancer cell 
line. 
1.6.1 Synthesis of Indoline SHetA2 Analogs 
 In this study, we synthesized Flex-Hets with an N-methylindoline Ring A system, 
including urea and thiourea linker units, as well as 4-NO2, CN, CF3, and OCF3 substituents in 
Ring B (26-33). These compounds were evaluated for anti-cancer activity against the human 
A2780 ovarian cancer cell line. None of the prepared compounds showed useful activity, but a 
new method for the synthesis of analogs was developed. 
1.6.2 Synthesis of Dihydrofuran SHetA2 Analogs 
 In this study, we synthesized Flex-Hets with a dihydrofuran Ring A system, including 
urea and thiourea linker units, and 4–NO2, CN, CF3, and OCF3 groups in Ring B to yield 40-47. 
These compounds were evaluated for anti-cancer activity against the human A2780 ovarian 
cancer cell line. Compounds 41 and 46 showed useful efficacy, and compounds 42 and 43 also 
showed improved potency from SHetA2. A useful method for the synthesis of heterocyclic 
analogs also was developed. 
1.6.3 Synthesis of OHet72 via a Reductive Heck Cyclization 
 In this study, we employed the method discovered in previous studies to synthesize 




1.6.4 Synthesis of Furan OHet72 Derivative via a Reductive Heck Cyclization 
 In this study, we were able to synthesize an analog of OHet72 17 by employing our 
facile, efficient method. 
1.7 Chemistry 
1.7.1 Synthesis of Indoline SHetA2 Analogs 
N-(2-Bromo-4-nitrophenyl)acetamide (19).  
2-Bromo-4-nitroaniline (18, 5.0 g, 23.0 mmol) was dissolved in acetic acid (50 mL), and acetic 
anhydride (10 mL) was added.  The mixture was stirred at room temperature for 18 hours, at 
which time TLC analysis (1:1 ether-hexane) indicated complete consumption of the starting 
material. The reaction mixture was poured into water (100 mL), at which time a yellow 
precipitate formed rapidly. The precipitate was collected via vacuum filtration and washed with 
copious amounts of water. The solid was dried under vacuum to yield 19 (5.00 g, 84%) as a 
yellow solid, mp 119-120 °C. IR: 3216, 1656, 1589, 1313 cm-1; 1H NMR (400 MHz, CDCl3): δ 
8.66 (d, J = 9.2 Hz, 1H), 8.46 (d, J = 2.5 Hz, 1H), 8.26 (dd, J = 9.2, 2.5 Hz, 1H), 7.89 (br s, 1H), 
2.32 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 168.5, 143.2, 141.3, 127.9, 124.2, 120.2, 11.8, 25.2.   
N-(2-Bromo-4-nitrophenyl)-N-(2-methylallyl)acetamide (20).  
N-(2-Bromo-4-nitrophenyl)acetamide (19, 5.00 g, 19.30 mmol) was dissolved in DMF (60 mL), 
and potassium carbonate (10.60 g, 77.20 mmol) was added. The mixture was stirred at room 
temperature under a N2 atmosphere for 10 minutes, at which time 3-iodo-2-methylprop-1-ene 
(7.00 g, 38.6 mmol) was added in one portion. The mixture was heated to 60 °C for 18 hours, 
after which time TLC analysis (1:2 ether-hexane) indicated completion of the reaction. The 
reaction mixture was poured into water (100 mL) and extracted with ethyl actetate (3 x 75 mL). 
The combined organic extracts were washed with water (2 x 75 mL) and brine (75 mL), dried 
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(Na2SO4), and concentrated under vacuum to afford 20 (6.02 g, 99%) as an orange oil. IR: 1652, 
1583, 1513, 1317 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.59 (d, J = 2.5 Hz, 1H), 8.24 (dd, J = 8.6, 
2.5 Hz, 1H), 7.41 (d, J = 8.6 Hz, 1H), 4.96 (d, J = 14.5 Hz, 1H), 4.86 (s, 1H), 4.66 (s, 1H), 3.52 
(d, J = 14.5 Hz, 1H), 1.87 (s, 3H), 1.81 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 169.2, 147.5, 
147.2, 140.0, 131.5, 129.2, 124.8, 123.5, 115.0, 52.7, 22.6, 20.6. 
1-(3,3-Dimethyl-5-nitroindolin-1-yl)ethan-1-one (21).  
N-(2-Bromo-4-nitrophenyl)-N-(2-methylallyl)acetamide (21, 4.40 g, 14.0 mmol) was dissolved in 
DMF (50 mL) and stirred at room temperature under a N2 atmosphere for five minutes. To the 
reaction mixture was added sodium acetate (2.84 g, 35.0 mmol), sodium formate (1.19 g, 17.50 
mmol), and tetraethylammonium chloride (2.33 g, 14.0 mmol). The resultant mixture was stirred 
at room temperature for an additional 10 minutes under a N2 atmosphere. Palladium acetate (0.30 
g, 10 mol%) was added in a single portion, along with 10 drops of water. The mixture was heated 
to 80 °C for 18 hours. TLC analysis was inconclusive as to the completion of the reaction. 
However, the presence of palladium particles in solution indicated likely completion. The 
reaction mixture was poured over a 1 cm Celite pad.  The remaining solution was then poured 
into water (150 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers 
were washed with water (2 x 50 mL), brine (75 mL), dried (Na2SO4), and concentrated under 
vacuum to afford 8 (2.78 g, 85%)  as a yellow solid, mp 183-184 °C. IR: 1674, 1571, 1375 cm-1; 
1H NMR (400 MHz, CDCl3): δ 8.59 (d, J = 9.0 Hz, 1H), 8.15 (dd, J = 9.0, 2.4 Hz, 1H), 8.00 (d, J 
= 2.4 Hz, 1H), 3.91 (s, 2H), 2.28 (s, 3H), 1.42 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 169.6, 
146.9, 143.9, 141.7, 124.9, 118.0, 116.4, 64.1, 40.1, 28.7, 24.3. 
3,3-Dimethyl-5-nitroindoline (22). 
1-(3,3-Dimethyl-5-nitroindolin-1-yl)ethan-1-one (21, 2.70 g, 11.50 mmol) was placed in 20% 
HCl (50 mL), and heated to 110 °C.  After one hour, all solid had dissolved, indicating reaction 
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completion. The mixture was poured into 1 M NaOH (150 mL).  The aqueous mixture was 
extracted with ethyl acetate (3 x 75 mL). The combined organic layers were washed with brine 
(100 mL), dried (Na2SO4), and concentrated under vacuum to afford 22 (2.07 g, 94%) as a yellow 
solid, mp 74-76 °C. IR: 3388, 1558, 1363 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.03 (dd, J = 8.7, 
2.3 Hz, 1H), 7.90 (d, J = 2.3 Hz, 1H), 6.49 (d, J = 8.7 Hz, 1H), 4.45 (br s, 1H), 3.49 (s, 2H), 1.35 
(s, 6H); 13C NMR (100 MHz, CDCl3): δ 155.9, 139.2, 138.2, 126.1, 118.9, 106.6, 61.7, 41.1, 27.9. 
1,3,3-Dimethyl-5-nitroindoline (23). 
A suspension of sodium hydride in DMF was prepared by washing 60% NaH (0.25 g, 6.00 mmol) 
in mineral oil with hexane three times, and then diluted with DMF (5 mL). 3,3-Dimethyl-5-
nitroindoline (22, 1.00 g, 5.2 mmol) was dissolved in DMF (10 mL), and added at room 
temperature to the NaH suspension via an addition funnel over 5 minutes. After all the NaH had 
been consumed, methyl iodide (0.80 g, 5.70 mmol) in DMF (5 mL) was added via an addition 
funnel. The reaction mixture was heated to 40 °C for 1 hour, at which time TLC analysis (1:2 
ether-hexane) indicated completion of the reaction. The reaction was quenched slowly with brine 
(50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed 
with water (3 x 30 mL), brine (30 mL), dried (Na2SO4), and concentrated under vacuum to afford 
23 (1.05 g, 99%) as a yellow oil. IR: 1551, 1359 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.08 (dd, J 
= 8.8, 2.3 Hz, 1 H), 7.83 (d, J = 2.3 Hz, 1H), 6.29 (d, J = 8.8 Hz, 1H), 3.36 (s, 2H), 2.92 (s, 3H), 
1.35 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 155.9, 139.2, 138.2, 126.1, 118.9, 106.6, 61.7, 41.1, 
37.4, 27.9 
1,3,3-Trimethylindolin-5-amine (24). 
1,3,3-Trimethyl-5-nitroindoline (23, 1.05 g, 5.10 mmol) was placed in an ethanol-water mixture 
(4:1, 60 mL).  Iron powder (1.15 g, 20.4 mmol) and ammonium chloride (0.35 g, 6.375 mmol) 
were added, and the mixture was heated at 85 °C for 2 hours, at which time TLC analysis (1:1 
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ether-hexane) indicated complete consumption of the starting material. The reaction mixture was 
filtered through a 1 cm Celite pad, which was washed with additional ethanol. The volume of 
ethanol was reduced under vacuum, and then the mixture was diluted with saturated sodium 
bicarbonate (100 mL). The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The 
combined organic extracts were washed with a brine and sodium bicarbonate mixture (1:1, 50 
mL), dried (Na2SO4), and the solvent removed under vacuum to afford 24 (0.90 g, 80%) as a 
purple oil. IR: 3421, 3347 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.49 (dd, J = 75 Hz, 1H), 6.36 (d, 
J = 7.5 Hz, 1H), 3.23 (br s, 2H), 2.96 (s, 2H), 2.67 (s, 3H), 1.26 (s, 6H); 13C NMR (100 MHz, 
CDCl3): δ 145.5, 140.8, 138.5, 114.3, 71.1, 40.4, 37.4, 27.1. 
1-(4-Nitrophenyl)-3-(1,3,3-trimethylindolin-5-yl)urea (26). 
1,3,3-Trimethylindolin-5-amine (24, 0.090 g 0.51 mmol) was dissolved in THF (5 mL). The 
resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 atmosphere. 1-
Isocyanato-4-nitrobenzene (25a, 0.094 g, 0.57 mmol) dissolved in THF (5 mL) was added 
dropwise over a period of 15 minutes. Upon completion of the addition, the solution was allowed 
to warm to room temperature and was stirred at room temperature for 24 hours, at which time 
TLC analysis (100% ether) indicated the complete consumption of the amine. The solvent was 
removed under vacuum, and the resultant solid was loaded onto an eight inch silica column. 
Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 26 (0.125g, 
72%) as a yellow solid, mp 204-206 °C. IR: 3304, 3192, 1541, 1334 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 9.29 (s, 1H), 8.52 (s, 1H), 8.17 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.17 (s, 
1H), 7.02 (d, J = 8.3 Hz, 1H), 6.46 (d, J = 8.3 Hz, 1H), 2.99 (s, 2H), 2.66 (s, 3H), 1.23 (s, 6H); 13C 
NMR (100 MHz, DMSO-d6): δ 152.6, 148.5, 147.3, 141.1, 139.7, 130.2, 125.6, 119.5, 117.6, 




1,3,3-Trimethylindolin-5-amine (24, 0.086 g, 0.48 mmol) was dissolved in THF (5 mL). The 
resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 atmosphere. 1-
Isothiocyanato-4-nitrobenzene (25b, 0.098 g, 0.54 mmol) dissolved in THF (5 mL) was added 
dropwise over a period of 15 minutes. Upon completion of the addition, the solution was allowed 
to warm to room temperature and was stirred at room temperature for 24 hours, at which time 
TLC analysis (100% ether) indicated the complete consumption of the amine. The solvent was 
removed under vacuum, and the resultant solid was loaded onto an eight inch silica column. 
Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 27 (0.128 g, 
75%) as a red solid, mp 156-158 °C. IR: 3330, 3195, 1545, 1337 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 8.18 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 8.8 Hz, 2H), 7.69 (s, 1H), 7.01 (d, J = 8.4 Hz, 
1H), 6.88 (s, 1H), 6.45 (d, J = 8.4 Hz, 1H), 3.20 (s, 2H), 2.81 (s, 3H), 1.31 (s, 6H); 13C NMR (100 
MHz, CDCl3): δ 179.7, 152.2, 144.3, 141.6, 126.4, 124.4, 122.7, 120.3, 107.1, 69.9, 40.3, 35.1, 
27.5. 
1-(4-(Trifluoromethyl)phenyl)-3-(1,3,3-trimethylindolin-5-yl)thiourea (28). 
1,3,3-trimethylindolin-5-amine (24, 0.086 g, 0.48 mmol) was dissolved in THF (5 mL). The 
resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 atmosphere. 1-
Isothiocyanato-4-(trifluoromethyl)benzene (25c, 0.107 g, 0.54 mmol) dissolved in THF (5 mL) 
was added dropwise over a period of 15 minutes. Upon completion of the addition, the solution 
was allowed to warm to room temperature and was stirred at room temperature for 24 hours, at 
which time TLC analysis (100% ether) indicated the complete consumption of the amine. The 
solvent was removed under vacuum, and the resultant solid was loaded onto an eight inch silica 
column. Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 28 
(0.091 g, 51%) as a grey solid, mp 161-163 °C. IR: 3321, 3186 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 7.68 (s, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.58 (coincident d, J = 8.4 Hz, 2H and s, 1H), 
7.02 (dd, J = 8.2, 2.2, 1H), 6.90 (d, J = 2.2 Hz, 1H), 6.45 (d, J = 8.2 Hz, 1H), 3.18 (s, 2H), 2.80 (s, 
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3H), 1.31 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 180.1, 152.0, 141.4, 141.4, 127.6, 127.3, 
126.3, 125.9, 125.8, 123.8, 120.3, 107.1, 70.0, 40.3, 35.2, 27.5. 
1-(4-(Trifluoromethyl)phenyl)-3-(1,3,3-trimethylindolin-5-yl)urea (29). 
1,3,3-Trimethylindolin-5-amine (24, 0.080 g, 0.46 mmol) was dissolved in THF (5 mL). The 
resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 atmosphere. 1-
Isocyanato-4-(trifluoromethyl)benzene (25d, 0.092 g, 0.50 mmol) dissolved in THF (5 mL) was 
added dropwise over a period of 15 minutes. Upon completion of the addition, the solution was 
allowed to warm to room temperature and was stirred at room temperature for 24 hours at which 
time TLC analysis (100% ether) indicated the complete consumption of the amine. The solvent 
was removed under vacuum, and the resultant solid was loaded onto an eight inch silica column. 
Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 29 (0.079 g, 
48%) as a white solid, mp 185-187 °C. IR: 3362, 3238 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.51 
(d, J = 8.7 Hz, 1H), 7.46 (d, J = 8.7 Hz, 2H), 6.99 (d, J = 8.1 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 
6.72 (s, 1H), 6.44 (d, J = 8.1 Hz, 1H), 6.25 (s, 1H), 3.14 (s, 2H), 2.78 (s, 3H), 1.30 (s, 6H); 13C 
NMR (100 MHz, CDCl3): δ 154.4, 141.8, 140.9, 126.2, 125.6, 124.9, 124.6, 122.9, 118.8, 118.5, 
70.2, 40.3, 35.7, 27.3.  
 
1-(4-Cyanophenyl)-3-(1,3,3-trimethylindolin-5-yl)thiourea (30). 
1,3,3-Trimethylindolin-5-amine (24, 0.072 g, 0.41 mmol) was dissolved in THF (5 mL). The 
resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 atmosphere. 4-
Isothiocyanatobenzonitrile (25e, 0.072 g, 0.45 mmol) dissolved in THF (5 mL) was added 
dropwise over a period of 15 minutes. Upon completion of the addition, the solution was allowed 
to warm to room temperature and was stirred at room temperature for 24 hours, at which time 
TLC analysis (100% ether) indicated the complete consumption of the amine. The solvent was 
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removed under vacuum, and the resultant solid was loaded onto an eight inch silica column. 
Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 30 (0.085 g, 
62%) as a white solid, mp 158-160 °C. IR: 3306, 3188, 2234 cm-1; 1H NMR (400 MHz, CDCl3): 
δ 7.74 (s, 1H), 7.71 (d, J = 8.5 Hz, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.01 (dd, J = 8.1, 2.2 Hz, 1H), 
6.45 (d, J = 2.2 Hz, 1H), 3.19 (2, 2H), 2.80 (s, 3H), 1.30 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 
179.7, 152.1, 142.5, 141.5, 132.7, 126.4, 124.3, 123.4, 120.3, 118.7, 108.4, 107.1, 69.9, 40.3, 
35.2, 27.5. 
1-(4-Cyanophenyl)-3-(1,3,3-trimethylindolin-5-yl)urea (31). 
1,3,3-Trimethylindolin-5-amine (24, 0.072 g 0.41 mmol) was dissolved in THF (5 mL). The 
resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 atmosphere. 4-
Isocyanatobenzonitrile (25f, 0.065 g, 0.45 mmol) dissolved in THF (5 mL) was added dropwise 
over a period of 15 minutes. Upon completion of the addition, the solution was allowed to warm 
to room temperature and was stirred at room temperature for 24 hours, at which time TLC 
analysis (100% ether) indicated the complete consumption of the amine. The solvent was 
removed under vacuum, and the resultant solid was loaded onto an eight inch silica column. 
Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) gave 31 (0.094 g, 
72%) as a white solid, mp 212-214 °C. IR: 3356, 3218, 2221 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 9.04 (s, 1H), 8.45 (s, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.8 Hz, 2H), 7.15 
(d, J = 2.2 Hz, 1H), 7.00 (dd, J = 8.2, 2.2 Hz, 1H), 6.45 (d, J = 8.2 Hz, 1H), 2.99 (s, 2H), 2.66 (s, 
3H), 1.23 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 152.8, 140.1, 133.7, 130.4, 119.9, 119.4, 
118.2, 114.7, 107.8, 103.2, 70.5, 40.3, 36.7, 27.5. 
1-(4-(Trifluoromethoxy)phenyl)-3-(1,3,3-trimethylindolin-5-yl)thiourea (32). 
1,3,3-Trimethylindolin-5-amine (24, 0.072 g, 0.41 mmol) was dissolved in THF (5 mL). The 
resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 atmosphere. 1-
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Isothiocyanato-4-(trifluoromethoxy)benzene (25g, 0.100 g, 0.45 mmol) dissolved in THF (5 mL) 
was added dropwise over a period of 15 minutes. Upon completion of the addition, the solution 
was allowed to warm to room temperature and was stirred at room temperature for 24 hours, at 
which time TLC analysis (100% ether) indicated the complete consumption of the amine. The 
solvent was removed under vacuum, and the resultant solid was loaded onto an eight inch silica 
column. Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 32 
(0.034 g, 21%) as a yellow solid, mp 131-133 °C. IR: 3312, 3201 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 7.68 (s, 1H), 7.50 (d, J = 8.5 Hz, 2H), 7.47 (s, 1H), 7.19 (d, J = 8.5 Hz, 2H), 7.02 (dd, J 
= 8.2, 2.2 Hz, 1H), 6.90 (d, J = 2.2 Hz, 1H), 6.44 (d, J = 8.2 Hz, 1H), 3.17 (s, 2H), 2.79 (s, 3H), 
1.30 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 180.2, 150.1, 144.8, 139.5, 139.4, 129.8, 125.6, 
124.8, 121.5, 119.5, 107.2, 70.3, 40.3, 36.2, 27.5. 
1-(4-(trifluoromethoxy)phenyl)-3-(1,3,3-trimethylindolin-5-yl)urea (33). 
1,3,3-Trimethylindolin-5-amine (24, 0.072 g 0.41 mmol) was dissolved in THF (5 mL). The 
resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 atmosphere. 1-
Isocyanato-4-(trifluoromethoxy)benzene 25g (0.092 g, 0.45 mmol) dissolved in THF (5 mL) was 
added dropwise over a period of 15 minutes. Upon completion of the addition, the solution was 
allowed to warm to room temperature and was stirred at room temperature for 24 hours, at which 
time TLC analysis (100% ether) indicated the complete consumption of the amine. The solvent 
was removed under vacuum, and the resultant solid was loaded onto an eight inch silica column. 
Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 33 (0.043 g, 
27%) as a yellow solid, mp 176-178 °C. IR: 3369, 3224 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 
8.71 (s, 1H), 8.30 (s, 1H), 7.53 (d, J = 9.0 Hz, 2H), 7.25 (s, J = 9.0 Hz, 2H), 7.15 (d, J = 2.1 Hz, 
1H), 6.99 (dd, J = 8.2, 2.1 Hz, 1H), 6.44 (d, J = 8.2 Hz, 1H), 2.98 (s, 2H), 2.65 (s, 3H), 1.22 (s, 
6H); 13C NMR (100 MHz, DMSO-d6): δ 153.3, 148.2, 142.7, 139.9, 139.7, 130.9, 122.2, 122.1, 
119.5, 119.2, 114.6, 107.8, 70.6, 39.5, 36.7, 27.5. 
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1.7.2 Synthesis of Dihydrofuran SHetA2 Analogs 
2-Bromo-1-((2-methylallyl)oxy)-4-nitrobenzene (35). 
2-Bromo-4-nitrophenol (34, 5.0 g, 22.9 mmol) was dissolved in DMF (100 mL), and potassium 
carbonate (12.60 g, 91.6 mmol) was added.  The mixture was stirred under a N2 atmosphere for 
10 minutes.  3-Iodo-2-methylprop-1-ene (6.26 g, 34.4 mmol) was added in a single portion, and 
the reaction was stirred under N2 at room temperature for 18 hours, at which time TLC analysis 
(1:4 ether-hexane) indicated completion of the reaction.  The mixture was poured into water (200 
mL), and the aqueous layer was extracted with ether (3 x 100 mL).  The combined organic layers 
were washed with water (3 x 100 mL) and brine (100 mL), dried (Na2SO4) and concentrated 
under vacuum to afford 35 (4.32 g, 73%) as a tan solid, mp 40-42 °C. IR: 1538, 1516, 1345, 1241 
cm-1; 1H NMR (400 MHz, CDCl3): δ 8.47 (d, J = 2.7, 1H), 8.18 (dd, J = 9.1, 2.7, 1H), 6.94 (d, J = 
9.1, 1H), 5.17 (s, 1H), 4.61 (s, 2H), 1.87 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 160.0, 141.5, 
138.9, 129.1, 124.6, 113.9, 112.2, 112.0, 73.2, 19.2. 
3-Bromo-4-((2-methylallyl)oxy)aniline (36). 
2-Bromo-1-((2-methylallyl)oxy)-4-nitrobenzene (35, 4.0 g, 14.72 mmol) was dissolved in an 
ethanol/water mixture (100 ml, 4:1).  Ammonium chloride (1.0 g, 18.4 mmol) and iron metal (3.3 
g, 58.8 mmol) were added, and the mixture was heated at 85 °C for one hour, at which time TLC 
analysis (1:1 ether-hexane) indicated complete consumption of the starting material.  The reaction 
mixture was filtered through a 1 cm Celite pad.  The volume was reduced under vacuum, and the 
aqueous portion was diluted with saturated aq. NaHCO3 (100 mL).  The aqueous layer was 
extracted with ether (3 x 75 mL), and the combined organic layers were washed with brine (100 
mL), dried (Na2SO4), and concentrated under vacuum to afford 36 (3.27 g, 92%) as a red oil. IR: 
3423, 3348, 1521, 1243 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.88 (d, J = 2.6 Hz, 1H), 6.71 (d, J = 
8.6 Hz, 1H), 6.53 (dd, J = 8.6, 2.6 Hz, 1H), 5.12 (s, 1H), 4.97 (s, 1H), 4.37 (s, 2H), 3.46 (br s, 
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2H), 1.83 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 148.1, 141.4, 140.9, 120.1, 115.7, 114.9, 
113.2, 112.7, 73.6, 19.5. 
N-(3-Bromo-4-((2-methylallyl)oxy)phenyl)acetamide (37). 
3-Bromo-4-((2-methylallyl)oxy)aniline (36, 3.0 g, 12.38 mmol) was dissolved in glacial acetic 
acid (20 mL), and 10mL of acetic anhydride were added.  The reaction was stirred at room 
temperature for two hours, at which time TLC analysis indication completion of the reaction.  
The reaction mixture was poured into water (100 mL), and extracted with ether (3 x 75 mL).  The 
combined organic layers were washed with water (3 x 100 mL), saturated aq. NaHCO3 (3 x 100 
mL) and brine (100 mL), dried (Na2SO4), and concentrated under vacuum to afford 37 (3.13 g, 
89%) as a tan solid, mp 86-88 °C. IR: 3243, 1659 1523, 1239 cm-1; 1H NMR (400 MHz, CDCl3): 
δ 7.75 (br s, 1H), 7.68 (d, J = 2.6 Hz, 1H), 7.38 (dd, J = 8.8, 2.6 Hz, 1H), 6.80 (d, J = 8.8 Hz, 1H), 
5.13 (s, 1H), 4.99 (s, 1H), 4.44 (s, 1H), 2.14 (s, 3H), 1.83 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 
168.7, 151.9, 140.2, 131.9, 125.6, 120.6, 113.6, 113.0, 112.0, 72.8, 24.3, 19.4. 
N-(3,3-Dimethyl-2,3-dihydrobenzofuran-5-yl)acetamide (38). 
N-(3-Bromo-4-((2-methylallyl)oxy)phenyl)acetamide (37, 3.00 g, 10.58 mmol) was dissolved in 
DMF (40 mL), and sodium acetate (2.18 g, 26.25 mmol ), sodium formate (0.86 g, 12.68 mmol), 
and tetraethylammonium chloride (2.10 g, 12.68 mmol) were added.  The mixture was stirred 
under N2 for 10 minutes, and then palladium acetate (0.240 g, 10 mol%) and a few drops of water 
were added.  The reaction was heated to 90 °C for 18 hours, and then filtered through a 1 cm 
Celite pad.  The mixture was diluted with water (150 mL) and extracted with ether (3 x 75mL).  
The combined organic layers were washed with brine (100 mL), dried (Na2SO4), and 
concentrated under vacuum to afford 38 (2.05 g, 95%) as a tan solid, mp 124-126 °C. IR: 3239, 
1661, 1231 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.38 (d, J = 2.3 Hz, 1 H), 7.18 (br s, 1H), 7.05 
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(dd, J = 8.5, 2.3 Hz, 1H), 6.71 (d, J = 8.5 Hz, 1H), 4.22 (s, 2H), 2.14 (s, 3H), 1.33 (s, 6H); 13C 
NMR (100 MHz, CDCl3): δ 168.2, 156.0, 137.2, 131.0, 120.5, 115.8, 109.5, 84.8 42.2, 27.4, 24.3. 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39). 
N-(3,3-Dimethyl-2,3-dihydrobenzofuran-5-yl)acetamide (38, 2.00 g 10.27 mmol) was placed in 
50 mL of 20% HCl and stirred for one hour at 90 °C.  At this time, all the material was dissolved, 
indicating completion of the reaction. The mixture was poured into 100 mL of 1 M NaOH 
solution.  The aqueous solution was then extracted with ethyl acetate (3 x 50 mL), and the 
combined organic layers were washed with brine (100 mL), dried (Na2SO4), and concentrated 
under vacuum to afford 39 (1.30 g, 82%) as a brown oil. IR: 3423, 3348, 1239 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 6.60 (d, J = 8.2, 1.4 Hz, 1H), 6.50 (d, J = 2.4 Hz, 1H), 6.47 (dd, J = 8.2, 2.4 
Hz, 1H), 4.16 (d, J = 8.5, 1H), 3.41 (s, 2H), 2.14 (s, 3H), 1.33 (s, 6H); 13C NMR (100 MHz, 
CDCl3): δ 152.3, 140.0, 137.5, 114.7, 110.2, 109.7, 84.3, 42.2, 27.2. 
1-(3,3-Dimethyl-2,3-dihydrobenzofuran-5-yl)-3-(4-nitrophenyl)thiourea (40). 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39, 0.062 g, 0.377 mmol) was dissolved in THF 
(5 mL).  The resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 
atmosphere. 1-Isothiocyanato-4-nitrobenzene (25a, 0.075 g, 0.415 mmol) dissolved in THF (5 
mL) was added dropwise over a period of 15 minutes.  Upon completion of the addition, the 
solution was allowed to warm to room temperature and was stirred at room temperature for 24 
hours, at which time TLC analysis (100% ether) indicated the complete consumption of the 
amine.  The solvent was removed under vacuum, and the resultant solid was loaded onto an eight 
inch silica column.  Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) 
yielded 40 (0.070 g, 54%) as a white solid, mp 178-180 °C. IR: 3308, 3195, 1542, 1334 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ 10.23 (s, 1H), 10.07 (s, 1H), 8.18 (d, J = 9.1 Hz, 2H), 7.82 (d, J = 
9.1 Hz, 2H), 7.24 (d, J = 2.3 Hz, 1H), 7.12 (dd, J = 8.4, 2.3 Hz, 1H), 6.75 (d, J = , 8.4 Hz, 1H), 
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4.23 (s, 2H), 1.28 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 180.0, 156.9, 146.9, 142.6, 137.3, 
132.2, 125.2, 124.8, 121.9, 120.1, 109.4, 82.5, 40.0, 27.6. 
1-(3,3-Dimethyl-2,3-dihydrobenzofuran-5-yl)-3-(4-nitrophenyl)urea (41). 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39, 0.062 g, 0.377 mmol) was dissolved in THF 
(5 mL).  The resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 
atmosphere.  1-Isocyanato-4-nitrobenzene (25b, 0.068 g, 0.415 mmol) dissolved in THF (5 mL) 
was added dropwise over a period of 15 minutes.  Upon completion of the addition, the solution 
was allowed to warm to room temperature and was stirred at room temperature for 24 hours, at 
which time TLC analysis (100% ether) indicated the complete consumption of the amine.  The 
solvent was removed under vacuum, and the resultant solid was loaded onto an eight inch silica 
column.  Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 41 
(0.073 g, 72%) as a yellow solid, mp 219-221°C. IR: 3336, 3199, 1546, 1329 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 9.35 (s, 1H), 8.68 (s, 1H), 8.18 (d, J = 8.9 Hz, 2H), 7.79 (d, J = 8.9 Hz, 2H), 
7.37 (s, 1H), 7.07 (d, J = 8.5 Hz, 1H), 6.71 (d, J = 8.5 Hz, 1H), 4.19 (s, 2H), 1.29 (s, 6H); 13C 
NMR (100 MHz, DMSO-d6): δ 154.9, 152.6, 147.1, 141.2, 137.4, 132.5, 125.6, 119.7, 117.8, 
115.0, 109.5, 84.2, 42.2, 27.6. 
 
1-(4-Cyanophenyl)-3-(3,3-dimethyl-2,3-dihydrobenzofuran-5-yl)thiourea (42). 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39, 0.068 g, 0.41 mmol) was dissolved in THF (5 
mL).  The resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 
atmosphere.  4-Isothiocyanatobenzonitrile (25c, 0.083 g, 0.52 mmol) dissolved in THF (5 mL) 
was added dropwise over a period of 15 minutes.  Upon completion of the addition, the solution 
was allowed to warm to room temperature and was stirred at room temperature for 24 hours, at 
which time TLC analysis (100% ether) indicated the complete consumption of the amine.  The 
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solvent was removed under vacuum, and the resultant solid was loaded onto an eight inch silica 
column.  Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 42 
(0.090 g, 67%) as a white solid, mp 158-160 °C. IR: 3299, 3183, 2231 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 7.90 (br s, 1H), 7.68 (d, J = 8.7, 2H), 7.64 (br s, 1H), 7.61 (d, J = 8.7 Hz, 2H), 7.08 (dd, 
J = 8.3, 2.3 Hz, 1H), 7.04 (d, J = 2.3, 1H), 6.85 (d, J = 8.3 Hz, 1H), 4.32 (s, 2H), 1.36 (s, 6H); 13C 
NMR (100 MHz, DMSO-d6): δ 180.0, 156.8, 144.7, 137.3, 133.2, 133.1, 132.2, 125.2, 122.7, 
120.2, 119.6, 109.4, 105.5, 84.5, 40.1, 27.6. 
1-(4-Cyanophenyl)-3-(3,3-dimethyl-2,3-dihydrobenzofuran-5-yl)urea (43). 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39, 0.068 g, 0.41 mmol) was dissolved in THF (5 
mL).  The resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 
atmosphere.  4-Isocyanatobenzonitrile (25d, 0.075 g, 0.52 mmol) dissolved in THF (5 mL) was 
added dropwise over a period of 15 minutes.  Upon completion of the addition, the solution was 
allowed to warm to room temperature and was stirred at room temperature for 24 hours, at which 
time TLC analysis (100% ether) indicated the complete consumption of the amine.  The solvent 
was removed under vacuum, and the resultant solid was loaded onto an eight inch silica column.  
Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) yielded 43 (0.0120 
g, 95%) as a white solid, mp 188-190 °C. IR: 3349, 3204, 2226 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 7.55 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 2H), 7.12 (d, J = 2.2 Hz, 1H), 6.99 (dd, J 
= 8.4, 2.2 Hz, 1H), 6.89 (br s, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.52 (br s, 1H), 4.27 (s, 2H), 1.34 (s, 
6H); 13C NMR (100 MHz, CDCl3): δ 157.5, 153.5, 142.8, 138.3, 133.9, 133.3, 133.2, 129.3, 
119.1, 119.0, 110.2, 105.7, 85.0, 42.1, 27.4. 
1-(3,3-Dimethyl-2,3-dihydrobenzofuran-5-yl)-3-(4-(trifluoromethyl)phenyl)urea (44). 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39, 0.068 g, 0.41 mmol) was dissolved in THF (5 
mL).  The resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 
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atmosphere.  1-Isocyanato-4-(trifluoromethyl)benzene (25e, 0.097 g, 0.51 mmol) dissolved in 
THF (5 mL) was added dropwise over a period of 15 minutes.  Upon completion of the addition, 
the solution was allowed to warm to room temperature and was stirred at room temperature for 24 
hours, at which time TLC analysis (100% ether) indicated the complete consumption of the 
amine.  The solvent was removed under vacuum, and the resultant solid was loaded onto an eight 
inch silica column.  Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) 
yielded 44 (0.037 g, 24%) as a grey solid, mp 221-223 °C. IR: 3304, 3191 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 9.00 (s, 1H), 8.55 (s, 1H), 7.65 (d, J = 8.6 Hz, 2H), 7.61 (d, J = 8.6 Hz, 2H), 
7.36 (d, J = 1.5 Hz, 1H), 7.05 (dd, J = 8.4, 1.5 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 4.18 (s, 2H), 
1.29 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 154.7, 153.0, 144.2, 137.4, 132.8, 126.5, 126.4, 
122.1, 119.5, 118.1, 114.8, 109.5, 84.2, 42.2, 27.6. 
1-(3,3-Dimethyl-2,3-dihydrobenzofuran-5-yl)-3-(4-(trifluoromethyl)phenyl)thiourea (45). 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39, 0.068 g, 0.41 mmol) was dissolved in THF (5 
mL).  The resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 
atmosphere.  1-Isocyanato-4-(trifluoromethyl)benzene (25f, 0.105 g, 0.52 mmol) dissolved in 
THF (5 mL) was added dropwise over a period of 15 minutes.  Upon completion of the addition, 
the solution was allowed to warm to room temperature and was stirred at room temperature for 24 
hours, at which time TLC analysis (100% ether) indicated the complete consumption of the 
amine.  The solvent was removed under vacuum, and the resultant solid was loaded onto an eight 
inch silica column.  Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) 
yielded 45 (0.085 g, 52%) as a white solid, mp 152-154 °C. IR: 3289, 3178 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 9.94 (s, 1H), 9.85 (s, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 
7.22 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.74 (d, J = 8.4, Hz, 1H), 4.22 (s, 2H), 
1.28 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 180.3, 156.8, 144.0, 137.2, 132.3, 126.2, 126.0, 




3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39, 0.086 g, 0.525 mmol) was dissolved in THF 
(5 mL).  The resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 
atmosphere.  1-Isocyanato-4-(trifluoromethoxy)benzene (25h, 0.128 g, 0.631 mmol) dissolved in 
THF (5 mL) was added dropwise over a period of 15 minutes.  Upon completion of the addition, 
the solution was allowed to warm to room temperature and was stirred at room temperature for 24 
hours, at which time TLC analysis (100% ether) indicated the complete consumption of the 
amine.  The solvent was removed under vacuum, and the resultant solid was loaded onto an eight 
inch silica column.  Elution with ether-hexane (gradient increasing from 10% ether to 50% ether) 
yielded 46 (0.097 g 48%) as a white solid, mp 224-226 °C. IR: 3341, 3193 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 8.76 (s, 1H), 8.46 (s, 1H), 754 (d, J = 8.8 Hz, 2H), 7.35 (d, J = 2.3 Hz, 1H), 
7.26 (d, J = 8.8 Hz, 2H), 7.04 (dd, J = 8.6, 2.3 Hz, 1H), 6.68 (d, J = 8.5 Hz, 1H), 4.18 (s, 2H), 
1.28 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 154.5, 153.2, 142.9, 142.9, 139.7, 137.3, 133.0, 




3,3-Dimethyl-2,3-dihydrobenzofuran-5-amine (39, 0.086 g, 0.525 mmol) was dissolved in THF 
(5 mL).  The resultant solution was cooled to 0 °C in an ice bath while stirring under a N2 
atmosphere.  1-Isothiocyanato-4-(trifluoromethoxy)benzene (25h, 0.138 g, 0.631 mmol) 
dissolved in THF (5 mL) was added dropwise over a period of 15 minutes.  Upon completion of 
the addition, the solution was allowed to warm to room temperature and was stirred at room 
temperature for 24 hours at which time TLC analysis (100% ether) indicated the complete 
consumption of the amine.  The solvent was removed under vacuum, and the resultant solid was 
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loaded onto an eight inch silica column.  Elution with ether-hexane (gradient increasing from 
10% ether to 50% ether) yielded 47 (0.079 g, 37%) as a white solid, mp 148-150 °C. IR: 3307, 
3195 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.69 (s, 1H), 9.68 (s, 1H), 7.56 (d, J = 9.0 Hz, 2H), 
7.31 (d, J = 9.0 Hz, 2H), 7.20 (d, J = 2.3 Hz, 1H), 7.08 (dd, J = 8.5, 2.3 Hz, 1H), 6.73 (d, J = 8.5 
Hz, 1H), 4.22 (s, 2H), 1.28 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 180.5, 156.7, 144.9, 
139.3, 137.3, 132.4, 125.7, 125.4, 121.9, 121.5, 120.3, 109.3, 84.5, 42.0, 27.6. 
1.7.3 Synthesis of OHet72 via a Reductive Heck Cyclization 
Ethyl 3-bromo-4-hydroxybenzoate (49). 
3-Bromo-4-hydroxybenzoic acid (48, 15.00 g, 69.1 mmol) was dissolved in ethanol (200 mL), 
and 1 mL of concentrated H2SO4 was added. The solution was heated at reflux for 3 days, and 
then the volume was reduced under vacuum.  The residue was poured into water (200 mL), and 
the aqueous layer was extracted with ether (3 x 150 mL).  The combined organic layers were 
washed with saturated aq.  NaHCO3 (50 mL) and brine (100 mL), and dried (Na2SO4).  Removal 
of the solvent under vacuum gave 49 (14.61 g, 86%) as a white solid, mp 102-104 °C IR: 3244, 
1677, 1289 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.19 (d, J = 2.0 Hz, 1H), 7.93 (dd, J = 8.5, 2.0 
Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 5.92 (br s, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 
3H); 13C NMR (100 MHz, CDCl3): δ 165.1, 156.0, 133.8, 131.0, 124.4, 115.7, 110.0, 61.1, 14.3. 
Ethyl 3-bromo-4-((3-methylbut-3-en-1-yl)oxy)benzoate (50). 
Ethyl 3-bromo-4-hydroxybenzoate (49, 14.5 g, 59.2 mmol) and 3-methylbut-3-en-1-yl 4-
methylbenzenesulfonate (12.13 g, 59.2 mmol) were dissolved in dimethylformamide (DMF) (50 
mL), and K2CO3 (32.72 g, 237.0 mmol) was added.  The reaction mixture was stirred under N2 at 
80 °C for 18 hours, at which time TLC analysis indicated complete consumption of the starting 
phenol.  The reaction mixture was cooled to room temperature and then poured into water (200 
mL).  The aqueous layer was extracted with ether (3 x 100 mL), and the combined organic layers 
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were washed with water (3 x 100 mL), saturated aq. NaHCO3 (100 mL), brine (100 mL), and 
dried (Na2SO4). Removal of the solvent under vacuum gave the 50 (15.03 g, 81%) as a clear oil. 
IR: 1712, 1555 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.22 (d, J = 2.1 Hz, 1H), 7.96 (dd, J = 8.6, 
2.1 Hz, 1H), 6.90 (d, J = 8.6 Hz, 1H), 4.88 (s, 1H), 4.82 (s, 1H), 4.35 (q, J = 7.1 Hz, 2H), 4.19 (t, 
J = 6.8 Hz, 2H), 2.59 (t, J = 7.1 Hz, 2H), 1.85 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ 165.3, 158.8, 141.7, 134.8, 130.5, 124.0, 112.6, 111.8, 111.7, 68.1, 61.0, 36.9, 
23.0, 14.3. 
Ethyl 4,4-dimethylchromane-6-carboxylate (51). 
Ethyl 3-bromo-4-((3-methylbut-3-en-1-yl)oxy)benzoate (50, 14.75 g, 47.1 mmol) was dissolved 
in DMF (30 mL), and sodium acetate (9.60 g, 118 mmol), sodium formate (3.84 g, 56.5 g), and 
tetraethylammonium chloride (9.37 g, 56.5 mmol) were added to form a slurry.  Water (2 mL), 
and Pd(OAc)2 (1.06 g, 10 mol%) were added, and the reaction mixture was heated at 95 °C under 
N2 for 18 hours.  The mixture was cooled and filtered through a 1 cm Celite pad, and then 
partitioned between water (200 mL) and ether (100 mL).  The aqueous layer was extracted with 
ether (2 x 100 mL) and the three combined organic layers were washed with water (3 x 100 mL), 
brine (100 mL), and dried (Na2SO4).  Solvent was removed under vacuum to afford 51 (10.40 g, 
94%). as a clear oil. IR: 1695 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.00 (d, J = 2.1 Hz, 1H), 7.75 
(dd, J = 8.6, 2.1 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 4.24 (t, J = 5.3 Hz, 
2H), 1.85 (t, J = 5.4 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H), 1.85 (t, J = 5.4 Hz, 2H), 1.37 (t, J = 7.1 Hz, 
3H), 1.36 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 166.7, 157.7, 131.4, 129.1, 128.8, 122.5, 
116.9, 63.4, 60.6, 37.1, 30.8, 30.6, 14.4. 
4,4-Dimethylchromane-6-carboxylic acid (52). 
Ethyl 4,4-dimethylchromane-6-carboxylate (51, 10.00 g, 42.7 mmol) was placed in an ethanol-
water mixture (2:1, 150 mL), and KOH (4.80 g, 85.5 mmol) was added.  The reaction was stirred 
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at 80° C for 3 hours, at which time TLC analysis indicated the reaction was completed.  The 
volume was reduced under vacuum, and the residue was acidified with 1 M HCl to pH 2, and then 
the aqueous layer was extracted with DCM (3 x 100 mL).  The combined organic layers were 
washed with brine (100 mL) and dried (Na2SO4), and concentrated under vacuum to afford 52 
(7.85 g, 89%) as a white solid, mp 223-225 °C. IR: 3602-2563, 1685 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 8.00 (d, J = 2.1 Hz, 1H), 7.83 (dd, J = 8.6, 2.1 Hz, 1H), 6.83 (d, J = 8.6 Hz, 1H), 4.27 
(t, J = 5.4 Hz, 2H), 1.86 (t, J = 5.4 Hz, 2H), 1.37 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 171.2, 
158.6, 131.6, 130.0, 129.6, 121.2, 117.1, 63.5, 37.0, 30.8, 30.6.  
4-Formylphenyl 4,4-dimethylchromane-6-carboxylate (54). 
4,4-Dimethylchromane-6-carboxylic acid (52, 7.54 g, 36.6 mmol) and 4-hydroxybenzaldehyde 
(53, 4.46 g, 36.6 mmol) were dissolved in DCM (20 mL).  4-Dimethylaminopyridine (DMAP) 
(11.16 g, 91.5 mmol) was added, followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) (7.02 g, 36.6 mmol).  The reaction mixture was stirred at room temperature for 24 hours, 
and then washed with 1 M HCl (2 x 100 mL), saturated aq. NaHCO3 (100 mL) and brine (100 
mL), and then dried (Na2SO4).  Concentration under vacuum afforded a tan, oily solid. The 
material was recrystallized from ethanol (15 mL) to afford 54 (7.26 g, 64%) as a cream-colored 
solid, mp 127-128 °C. IR: 2832, 2726, 1731, 1695 cm-1; 1H NMR (400 MHz, CDCl3): δ 10.03 (s, 
1H), 8.14 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 8.6 Hz, 2H), 7.92 (dd, J = 8.6, 2.1 Hz, 1H), 7.40 (d, J = 
8.5 Hz, 2H), 6.88 (d, J = 8.6 Hz, 1H), 4.30 (t, J = 5.5 Hz, 2H), 1.89 (t, J = 5.5 Hz, 2H), 1.40 (s, 
6H); 13C NMR (100 MHz, CDCl3): δ 191.0, 164.5, 158.8, 156.0, 133.9, 131.9, 131.2, 130.0, 
129.6, 122.7, 120.7, 117.4, 63.6, 36.9, 30.8, 30.7. 
4-Formylphenyl 4,4-dimethylchromane-6-carboxylate thiosemicarbazone (16). 
4-Formylphenyl 4,4-dimethylchromane-6-carboxylate (54, 3.00 g, 9.7 mmol) was suspended in 
ethanol (20 mL), and the mixture was heated to 78 °C until a clear solution was formed. To the 
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hot solution was added thiosemicarbazide (0.970 g, 10.6 mmol) in water (81 mL) with three drops 
of glacial acetic acid. The solution was allowed to stir and slowly cool to room temperature 
overnight. At this time, white crystals were noted in the flask, so the mixture was further cooled 
to -20 °C for 24 hours. The mixture was allowed to warm to room temperature for 1 hour before 
collecting the crystals via vacuum filtration. The white crystals were dried under vacuum 
overnight to afford the final dried product 16 (2.80 g, 76%) mp 187-189 °C. IR: 3436, 3402, 
3263, 3166, 1729, 1601 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 11.47 (s, 1H), 8.22 (br s, 1H), 
8.07 (d, J = 1.8 Hz, 1H), 8.07 (br s, 1H), 7.91 (d, J = 8.6 Hz, 2H), 7.85 (dd, J = 8.6, 1.8 Hz, 1H), 
7.31 (d, J = 0.6 Hz, 2H), 6.92 (d, J = 8.6 Hz, 1H), 4.28 (t, J = 5.4 Hz, 2H), 1.86 (t, J = 5.4 Hz, 
2H), 1.35 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 178.5, 164.7, 158.7, 152.3, 141.8, 132.5, 
132.4, 129.8, 129.7, 128.9, 122.8, 121.0, 117.7,63.7, 36.6, 30.8, 30.7. 
1.7.4 Synthesis of Furan OHet72 Derivative via a Reductive Heck Cyclization 
Ethyl 3-bromo-4-((2-methylallyl)oxy)benzoate (55). 
Ethyl 3-bromo-4-hydroxybenzoate (49, 2.00 g, 8.16 mmol) was dissolved in DMF (10 mL), and 
3-iodo-2-methylprop-1-ene (1.78 g, 9.80 mmol) and K2CO3 (4.50 g, 32.65 mmol) were added.  
The mixture was heated at 60 °C for 4 hours, at which time TLC analysis indicated complete 
consumption of the starting material. The reaction mixture was poured into water (100 mL), and 
the aqueous layer was extracted with ether (3 x 50mL). The combined organic layers were 
washed with water (3 x 75 mL) and brine (75 mL), and then dried (Na2SO4).  The solvent was 
removed under vacuum to afford 55 (2.40 g, 98%) as a yellow oil. IR: 1716, 1595 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 8.24 (d, J = 2.1 Hz, 1H), 7.95 (dd, J = 8.6, 2.1 Hz, 1H), 6.88 (d, J = 8.6 Hz, 
1H), 5.17 (s, 1H), 4.56 (s, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.86 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 165.2, 158.5, 139.6, 134.8, 130.4, 124.1, 113.3, 112.2, 111.9, 72.6, 
61.0, 19.3, 14.4. 
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Ethyl 3,3-dimethyl-2,3-dihydrobenzofuran-5-carboxylate (56). 
Ethyl 3-bromo-4-((2-methylallyl)oxy)benzoate (55, 2.00 g, 6.70 mmol) was dissolved in DMF 
(10 mL), and sodium acetate (1.37 g, 16.7 mmol), sodium formate (0.550 g, 8.00 mmol),     
PhEt3NCl (1.83 g, 8.00 mmol), and Pd(OAc)2 (7.5 mg, 0.5 mol%) were added.  The reaction was 
heated to 95 °C for 18 hours.  The reaction mixture was cooled to room temperature over 2 hours 
and then diluted with ether (100 mL) and filtered through a 1 cm Celite pad. The organic layer 
was washed with water (3 x 100 mL) and brine (100 mL), and then dried (Na2SO4).  The solvent 
was removed under vacuum to afford a yellow oil. Crude NMR analysis indicated the presence of 
both the cyclized product and the enol ether rearrangement by-product. The mixture was purified 
via column chromatography on silica, eluting with 10% ether in hexanes. The cyclized product 56 
eluted first as a yellow oil (0.725 g, 50%). IR: 1698 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.89 
(dd, J = 8.4, 1.8 Hz, 1H), 7.80 (d, J = 1.8 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 4.35 (q, J = 7.1 Hz, 
2H), 4.31 (s, 2H), 1.38 (t, J = 7.1 Hz, 3H), 1.37 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 166.6, 
164.2, 137.1, 131.9, 125.1, 121.8, 109.5, 85.6, 60.6, 41.6, 27.6, 14.4. 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-carboxylic acid (57). 
Ethyl 3,3-dimethyl-2,3-dihydrobenzofuran-5-carboxylate (56, 0.625 g, 2.84 mmol) was dissolved 
in ethanol (20 mL), and KOH (0.500 g, 8.92 mmol) was added.  The reaction was stirred at room 
temperature for 3 hours, at which time TLC analysis indicated the reaction was completed.  The 
volume was reduced under vacuum, and the residue was acidified with 1 M HCl to pH 2.  The 
aqueous layer was extracted with DCM (3 x 50 mL). The combined organic layers were washed 
with brine (50 mL), dried (Na2SO4), and concentrated under vacuum to afford 57 (0.525 g, 96%) 
as a white solid, mp 162-165 °C. IR: 3572-2525, 1668 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.97 
(dd, J = 8.4, 1.8 Hz, 1H), 7.87 (d, J = 1.8 Hz 1H), 6.83 (d, J = 8.4 Hz, 1H), 4.34 (s, 2H), 1.38 (s, 
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6H); 13C NMR (100 MHz, CDCl3): δ 171.5, 164.1, 137.2, 131.9, 125.0, 121.9, 109.6, 85.5, 41.5, 
27.7. 
4-Formylphenyl 3,3-dimethyl-2,3-dihydrobenzofuran-5-carboxylate (58). 
3,3-Dimethyl-2,3-dihydrobenzofuran-5-carboxylic acid (57, 0.450 g, 2.34 mmol) and 4-
hydroxybenzaldehyde (53, 0.286 g, 2.34 mmol) were dissolved in DCM (20 mL).  4-
Dimethylaminopyridine (DMAP) (0.715 g, 5.86 mmol) was added, followed by 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (0.450 g, 2.34 mmol).  The reaction mixture was 
stirred at room temperature for 24 hours and was then washed with 1 M HCl (2 x 50 mL), 
saturated aq. NaHCO3 (50 mL), and brine (50 mL), and then dried (Na2SO4) and concentrated 
under vacuum to afford 58 (0.650 g, 94%) as a cream-colored solid, mp 85-87 °C. IR: 2742, 
1722, 1696 cm-1; 1H NMR (400 MHz, CDCl3): δ 10.03 (s, 1H), 8.06 (dd, J = 8.4, 1.9 Hz 1H), 7.97 
(d, J = 8.5 Hz, 2H), 7.94 (d, J = 1.9 Hz, 1H), 7.40 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.4 Hz, 1H), 
4.37 (s, 2H), 1.41 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 191.0, 164.3, 156.0, 137.5, 133.9, 
132.0, 131.2, 125.1, 122.6, 121.4, 109.8, 85.6, 41.6, 27.7. 
4-Formylphenyl 3,3-dimethyl-2,3-dihydrobenzofuran-5-carboxylate thiosemicarbazone 
(17). 
4-Formylphenyl 3,3-dimethyl-2,3-dihydrobenzofuran-5-carboxylate (58, 0.500 g, 1.69 mmol) 
was suspended in ethanol (10 mL), and the mixture was heated to 78 °C until a clear solution was 
formed. To the hot solution was added thiosemicarbazide (0.184 g, 2.03 mmol) in water (21 mL) 
with one drop of glacial acetic acid. The solution was allowed to stir and slowly cool to room 
temperature overnight. At this time, white crystals were noted in the flask. The mixture was 
further cooled to -20 °C for 24 hours. The resulting mixture was allowed to warm to room 
temperature for 2 hours before collecting the crystals via vacuum filtration. The white crystals 
were dried under vacuum overnight to afford the final dried product (17, 0.467 g, 75%) mp 186-
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188 °C. IR: 3439, 3275, 3138, 2887, 1713, 1598 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 11.46 
(s, 1H), 8.21 (br s, 1H), 8.08 (s, 1H), 8.06 (br s, 1H), 7.98 (d, J= 1.9 Hz, 1H), 7.96 (dd, J = 8.6 Hz, 
1.9, 1H), 7.91 (d, J = 8.6 Hz, 2H), 7.31 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 8.6 Hz, 2H), 4.38 (s, 2H), 
1.36 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 178.5, 164.6, 164.1, 152.3, 141.8, 138.3, 132.4, 











SYNTHESIS OF A POTENTIAL ANTIBIOTIC 
 
2.1 Introduction 
 Carbapenem-resistant bacterial infections is one of the most pressing health crises in the 
world today. According to the CDC’s 2019 Antibiotic Resistance Threat Report, over 2.8 million 
antibiotic-resistant bacterial infections occur in the United States alone each year, resulting in 
over 35,000 deaths.36 In order to counteract this rapidly developing issue, new bacterial cell 
membrane molecular targets need to be considered. Strategies to interrupt bacterial iron 




Figure 2.1: 4-Aminoisoindoline fragments. 
 The derivatives of 4-aminoisoindoline-1,3-dione (59) have been shown to interfere with 
the iron storage protein bacterioferritin (BfrB) in P. aeruginosa and therefore make promising 
synthetic targets.38 This study will address the synthesis of a unique derivative of 59.
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The compound of interest in this study is a derivative of 4-aminoisoindolin-1-one 60, and was 
designed to provide insight into problems observed in the synthesis of 4-aminoisoindoline-1,3-
dione derivatives. It was suspected that during the reductive amination used to assemble 4-
aminoisindoline-1,3-dione derivatives, unknown side reactions could occur making difficult 
separation of products and by-products (Scheme 2.1).  
 
Scheme 2.1: Synthesis of 4-aminoisoindoline derivatives via a reductive amination. 
By synthesizing lactone derivative 60, it can be determined if these side reactions are occurring. 
If by-products are not formed, and the derivative retains biological activity, 4-aminoisoindolin-1-
one derivatives could be useful in future studies. 
2.2 Synthesis of a 4-Aminoisoindolin-1-one Derivative 
 Interest in 4-aminoisoindolin-1-one functionalized antibiotic candidate 64 has developed 
because such a compound could provide information about the binding of the isoindoline unit to 
 
 Figure 2.2: 4-Aminoisoindolin-1-one functionalized antibiotic candidate. 
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BfrB as well as information about side reactions occurring within the synthesis.38 
2.2.1 Results and Discussion 
 4-((5-Chloro-2-hydroxybenzyl)amino)isoindolin-1-one (64) required 4 steps to prepare 
(Scheme 2.2). Important precursor 4-bromoisoindolin-1-one (67) was synthesized by following 
the literature procedure by Maugeri and coworkers.39 
 
Scheme 2.2: The synthetic approach to 4-((5-Chloro-2-hydroxybenzyl)amino)isoindolin-1-one. 
The toluoyl ester 65 was halogenated at a benzylic position via radical addition to afford the 
benzyl bromide ester 66 in quantitative yields. Next, 66 was exposed to ammonia inside a sealed 
tube and generated lactam 67 in 93% yield. Aniline derivative 56 was prepared via Ullmann 
coupling of 67 with ammonia to afford 68 in 65% yield. Finally, 64 was realized via reductive 
amination of aniline derivative 68 and aldehyde 69. 
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2.3 Conclusion  
 In summary, an isoindolin-1-one antibiotic candidate was synthesized. 
2.4 Chemistry  
Methyl 3-bromo-2-(bromomethyl)benzoate (66). 
Methyl 3-bromo-2-methylbenzoate (65, 5.00 g, 21.8 mmol) was dissolved in 1,2-dichloroethane 
(DCE) (100 mL).  N-Bromosuccinimide (NBS) (4.27 g, 24 mmol) and benzoyl peroxide (20 mg) 
were added.  The flask was partially wrapped in foil and placed under a heat lamp so that the 
mixture reached reflux.  After 30 minutes, TLC analysis indicated complete consumption of the 
starting material.  The volume was reduced under vacuum, and then the solution was diluted with 
dichloromethane (DCM) (200 mL).  The organic layer was then washed with water (100 mL), 
NaHCO3 solution (100 mL), brine (100 mL), and then dried (Na2SO4). Removal of the solvent 
under vacuum afforded 66 (6.70 g, >99%) as a clear oil in quantitative yield. IR: 1723 cm-1; 1H 
NMR (400 MHz, CDCl3): δ 7.88 (dd, J = 7.8, 1.3 Hz, 1H), 7.75 (dd, J = 7.9, 1.3 Hz, 1H), 7.22 (t, 
J = 7.9 Hz, 1H), 5.12 (s, 2H), 3.95 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 168.0, 142.5, 133.8, 
137.3, 129.8, 129.2, 123.9, 51.5, 26.7. 
4-Bromoisoindolin-1-one (67). 
Methyl 3-bromo-2-(bromomethyl)benzoate (66, 6.70 g, 21.7 mmol) was dissolved in methanol 
(30 mL) in a large sealed tube.  Aqueous ammonia (29%, 35 mL) was added, and the mixture was 
heated at 60 °C overnight.  The tube was opened carefully after cooling, and the volume of 
solution was reduced under vacuum, and the residue was dissolved in ethyl acetate (150 mL). The 
organic layer was washed with water (2 x 100 mL), brine (100 mL), and dried (Na2SO4).  The 
solvent was removed under vacuum to afford 67 (4.30 g, 93%) as a white solid, mp 207-209 °C. 
IR: 3328, 1639 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 8.81 (br s, 1H), 7.82 (dd, J = 7.7, 0.9 Hz, 
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1H), 7.70 (dd, J = 7.7, 0.9 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 4.31 (s, 2H); 13C NMR (100 MHz, 
DMSO-d6): δ 173.9, 144.5, 135.9, 132.2, 127.8, 126.3, 122.0, 45.4. 
4-Aminoisoindolin-1-one (68). 
4-Bromoisoindolin-1-one (67, 1.50 g, 7.1 mmol) was dissolved in dimethylformamide (DMF) (4 
mL) inside a sealed tube.  Aqueous ammonia (29%, 20mL), CuI (0.675 g, 3.55 mmol), and L-
proline (0.815 g, 7.1 mmol) were added, and the mixture was heated to 110 °C for 24 hours, at 
which time the solution turned from green to blue. The mixture was poured into NaHCO3 solution 
(100 mL), and the aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined 
organic layers were then washed with water (3 x 50 mL) and brine (50 mL), and dried (Na2SO4).  
The solvent was removed under vacuum to afford a brown solid.  The product was purified via 
column chromatography using pyrone-treated silica gel, and eluting with 10% ethyl acetate in 
DCM. The product 68 (0.680 g, 65%) was recovered as a yellow solid, mp 174-176 °C. IR: 3451, 
3358, 3325, 1621 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 8.33 (br s, 1H), 7.14 (t, J = 7.6 Hz, 
1H), 6.85 (dd, J = 7.5, 0.9 Hz, 1H), 6.75 (dd, J = 7.7, 0.9 Hz, 1H), 5.37 (br s, 2H), 4.11 (s, 2H); 
13C NMR (100 MHz, DMSO-d6): δ 173.9, 144.4, 131.9, 130.8, 127.8, 119.5, 117.3, 44.1. 
4-((5-Chloro-2-hydroxybenzyl)amino)isoindolin-1-one (64). 
4-Aminoisoindolin-1-one (68, 0.200 g, 1.35 mmol), 5-chloro-2-hydroxybenzaldehyde (69, 0.423 
g, 2.70 mmol), and acetic acid (0.190 mL) were placed in DMF (1.5 mL) under a N2 atmosphere.  
Upon stirring, a slurry formed quickly, and the solution was heated to 90°C for 1 hour.  During 
the hour, another 1.5 mL of DMF were added, and a clear solution resulted.  The mixture was 
then cooled to 0 °C, and sodium triacetoxyborohydride [NaBH(OAc)3] (0.860 g, 4.05 mmol) was 
added portion-wise over 15 minutes.  The mixture was warmed to 90 °C for 3 hours, and then 
cooled to room temperature and stirred overnight, at which time TLC analysis indicated complete 
consumption of the starting amine.  The mixture was carefully poured into water (50 mL), and the 
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aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were 
washed with NaHCO3 solution (2 x 50 mL), water (2 x 50 mL), and brine (50mL), and then dried 
(Na2SO4).  The solvent was removed under vacuum to afford a yellow residue. The product was 
purified via column chromatography using pyrone-treated silica gel. Elution with 10% ethyl 
acetate in hexanes afforded the excess aldehyde 69. Elution with 10% ethyl acetate in DCM, 
followed by increasing the gradient to 30% ethyl acetate, 5% methanol in DCM eluted the 
product 64 (0.281 g, 72%) as a yellow solid, mp 183-186 °C. IR: 3456, 3341, 3324, 1623 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 8.40 (br s, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.15 (d, J = 
2.9 Hz, 1H), 7.08 (dd, J = 8.4, 2.8 Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 6.84 (d, J = 8.6 Hz, 1H), 6.52 
(d, J = 7.7 Hz, 1H), 6.19 (t, J = 6.1 Hz, 1H), 4.30 (d, J = 6.0 Hz, 2H), 4.23 (s, 2H); 13C NMR (100 
MHz, DMSO-d6): δ 171.2, 154.3, 143.9, 133.6, 129.4, 129.2 128.3, 127.6, 127.5, 123.0, 116.9, 






MISCELLANEOUS CYCLIZATION ATTEMPTS 
3.1 Summary 
Numerous attempts were made to cyclize Ring A systems that could be of interest as 
SHetA2 analogs. These attempts were made to better understand the scope of the reductive Heck 
reaction using the Jeffery conditions. If a sufficiently broad scope could be established, this 
reaction would prove to be an exceptionally powerful tool for the synthesis of SHetA2 analogs. 
The conditions established by Liu and co-workers29 proved ineffective in initial attempts to form 
the heterocycles in Table 3.1, thus adjustments were made. The initial conditions incorporated 2.5 
equivalents (relative to the alkene starting material) of NaOAc as a base, 1.2 equivalents of 
NaHCO2 as a reductant, 1.2 equivalents of a tetraalkylammonium salt, and catalytic Pd(OAc)2 in 
DMF at 85 °C to cyclize the material. These conditions have proven useful to synthesize 26-33 
and 40-47. Altering the conditions proved effective in the synthesis of 17. 
Attempts at altering the conditions to enable cyclization were numerous, and incorporated 
nearly all possible combinations of the adjusted conditions. The adjusted conditions initially 
involved using K2CO3 or Et3N both in addition to, and in place of NaOAc, as the base. Secondly, 
high and low catalyst loadings were incorporated, including 10 mol% Pd(OAc)2 and 0.5 mol% 
Pd(OAc)2. Thirdly, the temperature of the reaction mixture was varied, including 65 °C, 75 °C, 
85 °C, and 95 °C. Lastly, the reaction time was varied from 3 to 6 to 12 to 18 to 24 hours. The
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aforementioned conditions were not exhausted for each example, but sufficient combinations 





Table 3.1: Attempts made at expanding the scope of the reductive Heck cyclization. 
Unfortunately, most substrates were prone to decompose, regardless of the reaction 
conditions. Several cases resulted in a mixture of cyclized material and starting material, but the 
crude yields were poor (<40%), and separation of the product proved exceptionally difficult. Each 
example in Table 3.1 features some characteristic that could prevent the desired cyclization from 
occurring, including functional groups thought to poison palladium catalysts,40 electron deficient 
aromatic rings, sterically hindered alkenes, and thermodynamically unfavorable ring sizes. While 
the reductive Heck reaction using the Jeffery conditions has proven to be a powerful tool to 
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synthesize N- and O-containing heterocycles relevant as SHetA2 analogs, several limitations 








This study used a potentially powerful, previously unused method to synthesize anti-
cancer drug candidates: an intramolecular reductive Heck cyclization using the Jeffery conditions. 
The nature of this reaction presented an interesting opportunity to discover a versatile method to 
synthesize SHetA2 (3) analogs. The reaction is known to prepare N- and O-containing 
heterocycles, and is capable of installing benzylic, geminal dimethyl groups, both of which are 
important to this study. This study also attempted to explore the scope of the reaction by initiating 
cyclizations of other substrates, many of which are not well understood.  
 Upon investigation, a method was established that proved capable of synthesizing N- and 
O-containing Ring A systems for SHetA2 analogs. The method proved to be effective for the 
preparation of 5- and 6-membered heterocycles with good functional group tolerance and good 
yields. This discovery lead us to conclude that this versatile method can be used to synthesize 
many future analogs of interest. Unfortunately, some apparent limitations of the reaction could 
not be overcome, as numerous cyclization attempts of S-containing heterocycles, pyridine 
substrates, and lactones proved incompatible. 
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Finally, this study produced a method to synthesize a potential antibiotic that could retain 
activity and minimizes likely side reactions in the synthesis. Testing of the compound will 
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NOAEL – No observed adverse effect level 
IC50 – Half maximal inhibitory concentration 
DMF – dimethylformamide 
DCM – dichloromethane, methylene chloride 
DCE – 1,2-dichloroethane 
DMAP – 4-dimethylaminopyridine 
EDC – 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
TLC – thin layer chromatography 
CDCl3 – deuterated chloroform 
DMSO-d6 – deuterated dimethylsulfoxide 
EtOH – ethanol 
AcOH – acetic acid 
NaOAc – sodium acetate 
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